Latest News - Oklahoma Society of Clinical Oncology

New FDA indication for IMFINZI® (durvalumab1,2 )

AstraZeneca recently announced that the US Food and Drug Administration (FDA) has approved a new indication for IMFINZI® (durvalumab1,2 ), in combination with IMJUDO® (tremelimumab-actl), for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). 1,2 This approval is based on results from the HIMALAYA trial, a Phase III, global, randomized, open-label, multicenter study […]

Read More

New FDA Approval for IMFINZI® (durvalumab)

The US Food and Drug Administration (FDA) has approved a new indication for IMFINZI® (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).1 BTCs comprise a heterogeneous group of rare cancers, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer, that account for […]

Read More

Medicare #MCED Screening Covering Act

Thanks to @SenatorLankford, the Medicare #MCED Screening Coverage Act now has 51 cosponsors in the Senate! This bill is a must-pass for Oklahoma seniors, who deserve to access the best possible tools to detect cancer early.

Read More

FDA Approval of Imbruvica

On August 24, 2022, the Food and Drug Administration approved ibrutinib (Imbruvica, Pharmacyclics LLC) for pediatric patients ≥ 1 year of age with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension. For more information, read the FDA Announcement or Press Release.

Read More

Reconciliation Bill With Medicare Drug Price Negotiation, Out-of-Pocket and Inflation Caps Becomes Law

On August 16, President Biden signed the Inflation Reduction Act—a broad climate, tax, and healthcare reconciliation bill—into law. The law extends ACA tax credit subsidies, allows Medicare to negotiate prescription drug prices, places inflationary caps on price increases for Medicare Part B and Part D drugs, and limits Medicare beneficiaries’ out-of-pocket spending on Part D […]

Read More

Pfizer Oncology announces a new FDA-approved indication for XALKORI® (crizotinib). 

Read the Full Prescribing Information

Read More

AstraZeneca announces additional approval for ENHERTU® (fam-trastuzumab deruxtecan-nxki)

AstraZeneca recently announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki) is now approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti–HER2-based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.1 ENHERTU has Boxed […]

Read More

FDA approves a new indication for LYNPARZA® (olaparib)

The US Food and Drug Administration (FDA) has approved a new indication for LYNPARZA® (olaparib) for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved […]

Read More

Register Now for OSCO’s “Best of” San Antonio Breast Cancer Symposium® Virtual Symposium to be held March 19, 2022

The Oklahoma Society of Clinical Oncology, Inc. would like to invite you to attend our 2022 Spring meeting. Join your colleagues to hear highlights from this state-of-the art symposium on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease. The “Best of” SABCS is an officially licensed program of the San Antonio […]

Read More

Natera Achieves Milestone of Enrolling First 1,000 Patients in its BESPOKE CRC Study

Clinical utility study in stage I-IV colorectal cancer (CRC) evaluates how adjuvant treatment decisions are impacted by using the Signatera™ MRD test Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a milestone with over 100 sites initiated and 1,000 patients enrolled across the U.S. in its BESPOKE CRC study, a prospective, […]

Read More